A Phase 3 interventional study of Oral treprostinil (UT-15C) Sustained Release Tablets and Placebo in Pulmonary Hypertension, sponsored by United Therapeutics. Completed at 77 sites in 13 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-01-03.
Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 5th largest by enrollment, is one of 2 that started in 2006, is one of 14 in phase 3, and was the 3rd registered.
701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 142 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:
Liquidia Technologies, Inc. · Sites in United States
Ages 18–80
University of Arizona · Sites in United States
Ages 18+
Shanghai Zhongshan Hospital
Ages 18–75
By country, each count listing its studies:
treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 12 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2006.
This study's enrollment of 349 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 32 across the 44 interventional studies. Of the 32 that completed or were terminated, 20 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
51 studies in Pulmonary Arterial Hypertension by United Therapeutics: 1 open now, 3 under way, 1 of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 51 studies in Pulmonary Arterial Hypertension by United Therapeutics, this one is the 7th largest by enrollment of the 45 interventional ones that give a count, is one of 2 that started in 2006, is one of 17 in phase 3, and was the 3rd registered.
United Therapeutics’s Pulmonary Arterial Hypertension studies by the year they started, since 2002.
1 of the studies testing treprostinil in Pulmonary Arterial Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07759804Liquidia Technologies, Inc.A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, from their registry updates:
Among United Therapeutics’s 51 in Pulmonary Arterial Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study was an international, multicenter, randomized (2:1 active:placebo), double-blind, placebo-controlled study in subjects with PAH who were NOT currently receiving approved therapy for their PAH. Study visits occurred at 4 week intervals for 12 weeks (with an additional visit at Week 11) with the key measure of efficacy being the 6-minute walk test. Study procedures included routine blood tests, medical history, physical exams, disease evaluation, and exercise tests. Two optional substudies were also a part of FREEDOM-M at select centers - a hemodynamic substudy with a right heart catheterization at Baseline and Week 12 and a genetics and biomarkers substudy with blood samples collected at Baseline and Week 12.
Patients who completed all assessments for 12 weeks were also eligible to enter an open-label, extension phase study (FREEDOM - EXT).
701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 142 are open to participants now.
This study's enrollment of 349 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Browse Pulmonary Arterial Hypertension studies →United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
Compared within Pulmonary Arterial Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension, Pulmonary. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects receive UT-15C (oral treprostinil) twice daily.
Drug: Oral treprostinil (UT-15C) Sustained Release Tablets
Subjects receive placebo (sugar pill) twice daily.
Other: Placebo
Sustained release oral tablet, twice daily
Also known as: treprostinil diethanolamine
Placebo oral tablet twice daily
Six Minute Walk Distance (6MWD)
Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 12, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 12. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.
Time frame: Baseline and Week 12
Six Minute Walk Distance (6MWD)
Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 11, a time expected to correlate with trough treprostinil concentration. The six minute walk test was to be conducted 8 to 13 hours after the previous dose of study drug. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 11. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.
Time frame: Baseline and Week 11
Six Minute Walk Distance (6MWD)
Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 8, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 8. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.
Time frame: Baseline and Week 8
Six Minute Walk Distance (6MWD)
Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 4, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 4. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.
Time frame: Baseline and Week 4
Clinical Worsening Assessment
Definition of clinical worsening included patients who met at least one of the following criteria during the 12 weeks of the study: 1. Death (all causes excluding accident) 2. Transplantation or atrial septostomy 3. Clinical deterioration as defined by: 1. Hospitalization as a result of PAH, or 2. greater than or equal to 20% decrease in 6MWD from Baseline (or too ill to walk) and a decrease in WHO functional class And 3. Initiation of new PAH specific therapy (i.e., ERA, PDE5-I, prostacyclin)
Time frame: Baseline and Week 12
World Health Organization Functional Classification for PAH
Class I: Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain, or near syncope. Class II: Patients with pulmonary hypertension resulting in slight limitation of physical activity. These patients are comfortable at rest, but ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III: Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Ordinary activity causes undue dyspnea or fatigue, chest pain, or near syncope. Class IV: Patients with pulmonary hypertension with inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may be present even at rest. Discomfort is increased by any physical activity.
Time frame: Baseline and Week 12
Borg Dyspnea Score
The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the 6-minute walk test. The Borg dyspnea score was assessed immediately following the 6-minute walk test. Scores ranged from 0 (for no shortness of breath) to 10 (for greatest shortness of breath ever experienced).
Time frame: Baseline and Week 12
Dyspnea-Fatigue Index
The dyspnea-fatigue index has three components, each rated on a scale of 0 to 4, for the magnitude of the task that evokes dyspnea or fatigue, the magnitude of the pace (or effort) with which the task is performed and the associated functional impairment in general activities. The ratings for each component were added to form an aggregate score, which could range from 0, for the worst condition, to 12, for the best.
Time frame: Baseline and Week 12
Symptoms of PAH
Defined symptoms of PAH including fatigue, dyspnea, edema, dizziness, syncope, chest pain, and orthopnea were assessed at Baseline prior to starting study drug and during the Treatment Phase at Week 12. Severity grade values (i.e., 0, 1, 2, or 3 in increasing severity) were assigned for each symptom.
Time frame: Baseline and Week 12
349 subjects participated in the study from 24 October 2006 to 29 April 2011 at 52 of 77 sites across the United States, Puerto Rico, Canada, Europe, Israel, India, Mexico, and China. The primary endpoint was analyzed using the primary analysis population which included 228 subjects who had access to 0.25 mg tablets at the time of randomization.
| Milestone | Placebo | UT-15C (Oral Treprostinil) |
|---|---|---|
| Started | 116 | 233 |
| Completed | 98 | 182 |
| Not completed | 18 | 51 |
Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 12, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 12. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.
| meters | Placebo | UT-15C (Oral Treprostinil) |
|---|---|---|
| 6MWD at Baseline | 339 (282 to 381) | 350 (283 to 386) |
| 6MWD at Week 12 | 343 (246 to 403) | 370 (300 to 418) |
| Change in 6MWD from Baseline to Week 12 | -5 (-41 to 49) | 25 (-16 to 63) |
Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 11, a time expected to correlate with trough treprostinil concentration. The six minute walk test was to be conducted 8 to 13 hours after the previous dose of study drug. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 11. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.
| meters | Placebo | UT-15C (Oral Treprostinil) |
|---|---|---|
| 6MWD at Baseline | 339 (282 to 381) | 350 (283 to 386) |
| 6MWD at Week 11 | 335 (254 to 400) | 350 (290 to 400) |
| Change in 6MWD from Baseline to Week 11 | 0 (-54 to 36) | 8 (-25 to 50) |
Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 8, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 8. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.
| meters | Placebo | UT-15C (Oral Treprostinil) |
|---|---|---|
| 6MWD at Baseline | 339 (282 to 381) | 350 (283 to 386) |
| 6MWD at Week 8 | 347 (240 to 398) | 355 (300 to 408) |
| Change in 6MWD from Baseline to Week 8 | 0 (-36 to 35) | 17 (-15 to 54) |
Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 4, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 4. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.
| meters | Placebo | UT-15C (Oral Treprostinil) |
|---|---|---|
| 6MWD at Baseline | 339 (282 to 381) | 350 (283 to 386) |
| 6MWD at Week 4 | 350 (254 to 387) | 360 (285 to 400) |
| Change in 6MWD from Baseline to Week 4 | 0 (-28 to 17) | 7 (-15 to 42) |
Definition of clinical worsening included patients who met at least one of the following criteria during the 12 weeks of the study: 1. Death (all causes excluding accident) 2. Transplantation or atrial septostomy 3. Clinical deterioration as defined by: 1. Hospitalization as a result of PAH, or 2. greater than or equal to 20% decrease in 6MWD from Baseline (or too ill to walk) and a decrease in WHO functional class And 3. Initiation of new PAH specific therapy (i.e., ERA, PDE5-I, prostacyclin)
| participants | Placebo | UT-15C (Oral Treprostinil) |
|---|---|---|
| Clinical Worsening Assessment | 8 | 15 |
Class I: Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain, or near syncope. Class II: Patients with pulmonary hypertension resulting in slight limitation of physical activity. These patients are comfortable at rest, but ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III: Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Ordinary activity causes undue dyspnea or fatigue, chest pain, or near syncope. Class IV: Patients with pulmonary hypertension with inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may be present even at rest. Discomfort is increased by any physical activity.
| participants | Placebo | UT-15C (Oral Treprostinil) |
|---|---|---|
| WHO Class I | 1 | 2 |
| WHO Class II | 29 | 59 |
| WHO Class III | 38 | 75 |
| WHO Class IV | 9 | 15 |
The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the 6-minute walk test. The Borg dyspnea score was assessed immediately following the 6-minute walk test. Scores ranged from 0 (for no shortness of breath) to 10 (for greatest shortness of breath ever experienced).
| units on a scale | Placebo | UT-15C (Oral Treprostinil) |
|---|---|---|
| Borg dyspnea score at Baseline | 3 (2 to 6) | 3 (2 to 4) |
| Borg dyspnea score at Week 12 | 3 (2 to 5) | 3 (1 to 5) |
| Change in Borg dyspnea score from Baseline to Wk12 | 0 (-1 to 1) | 0 (-1 to 1) |
The dyspnea-fatigue index has three components, each rated on a scale of 0 to 4, for the magnitude of the task that evokes dyspnea or fatigue, the magnitude of the pace (or effort) with which the task is performed and the associated functional impairment in general activities. The ratings for each component were added to form an aggregate score, which could range from 0, for the worst condition, to 12, for the best.
| units on a scale | Placebo | UT-15C (Oral Treprostinil) |
|---|---|---|
| Dyspnea-fatigue index at Baseline | 5.8 ± 2.4 | 6.2 ± 2.1 |
| Dyspnea-fatigue index at Week 12 | 5.5 ± 2.9 | 5.9 ± 2.8 |
| Change in dyspnea-fatigue index from BL to Wk 12 | -0.3 ± 2.5 | -0.3 ± 2.4 |
Defined symptoms of PAH including fatigue, dyspnea, edema, dizziness, syncope, chest pain, and orthopnea were assessed at Baseline prior to starting study drug and during the Treatment Phase at Week 12. Severity grade values (i.e., 0, 1, 2, or 3 in increasing severity) were assigned for each symptom.
| units on a scale | Placebo | UT-15C (Oral Treprostinil) |
|---|---|---|
| Change in fatigue symptoms | 0.1 ± 1.0 | 0.0 ± 1.0 |
| Change in dyspnea symptoms | -0.1 ± 0.9 | -0.2 ± 0.9 |
| Change in edema symptoms | 0.3 ± 1.0 | 0.2 ± 1.1 |
| Change in dizziness symptoms | 0.0 ± 1.0 | 0.3 ± 1.0 |
| Change in syncope symptoms | 0.3 ± 1.0 | 0.3 ± 0.9 |
| Change in chest pain symptoms | 0.1 ± 0.9 | 0.2 ± 1.0 |
| Change in orthopnea symptoms | 0.2 ± 0.9 | 0.2 ± 1.0 |
Exploratory efficacy analyses were to determine the effect of Baseline WHO functional class on treatment effect for change in 6MWD. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 12. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.
| meters | Placebo | UT-15C (Oral Treprostinil) |
|---|---|---|
| 6MWD at Baseline | 333.5 (269 to 382.5) | 330 (265 to 378) |
| 6MWD at Week 12 | 316.5 (231.5 to 385) | 354 (265 to 400) |
| Change in 6MWD from Baseline to Week 12 | -8.5 (-50.5 to 40) | 20.5 (-20 to 63) |
Exploratory efficacy analyses were to determine the effect of Baseline WHO functional class on treatment effect for change in 6MWD. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 12. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.
| meters | Placebo | UT-15C (Oral Treprostinil) |
|---|---|---|
| 6MWD at Baseline | 370 (297 to 378) | 366 (315 to 390) |
| 6MWD at Week 12 | 379 (274 to 429) | 391 (348 to 431) |
| Change in 6MWD from Baseline to Week 12 | 18 (-30 to 55) | 27 (-5 to 67) |
Exploratory efficacy analyses were to determine the effect of PAH etiology (idiopathic/heritable, associated with collagen vascular disease, and other etiologies) on treatment effect for change in 6MWD. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 12. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.
| meters | Placebo | UT-15C (Oral Treprostinil) |
|---|---|---|
| 6MWD at Baseline | 332.5 (260 to 379) | 346 (281 to 390) |
| 6MWD at Week 12 | 310.5 (242.5 to 380) | 380 (304 to 420) |
| Change in 6MWD from BL to Wk 12 | -7.5 (-50.5 to 42) | 25 (-13 to 67) |
Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 12, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). This outcome measure was assessed using data collected from all subjects enrolled in the study, regardless of tablet strength availability at randomization. The six minute walk test was to be conducted 3 to 6 house after the previous dose of study drug. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Wk 12. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference i
| meters | Placebo | UT-15C (Oral Treprostinil) |
|---|---|---|
| 6MWD at Baseline | 338.5 (265.5 to 383.5) | 347 (288 to 387) |
| 6MWD at Week 12 | 329.5 (231.5 to 397.5) | 370 (304 to 420) |
| Change in 6MWD from Baseline to Week 12 | 0 (-46 to 40) | 25 (-12 to 63) |
Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 11, a time expected to correlate with trough treprostinil concentration. This outcome measure was assessed using data from all subjects enrolled in the study, regardless of tablet strength availability at the time of randomization. The six minute walk test was to be conducted 8 to 13 hours after the previous dose of study drug. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 11. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.
| meters | Placebo | UT-15C (Oral Treprostinil) |
|---|---|---|
| 6MWD at Baseline | 338.5 (265.5 to 383.5) | 347 (288 to 387) |
| 6MWD at Week 11 | 326.5 (206 to 398) | 351 (303 to 403) |
| Change in 6MWD from Baseline to Week 11 | -2 (-58.5 to 36) | 6 (-18 to 48) |
Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 8, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). This outcome measure was assessed using data from all subjects enrolled in the study, regardless of tablet strength availability at randomization. The six minute walk test was to be conducted 3 to 6 house after the previous dose of study drug. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 8. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.
| meters | Placebo | UT-15C (Oral Treprostinil) |
|---|---|---|
| 6MWD at Baseline | 338.5 (265.5 to 383.5) | 347 (288 to 387) |
| 6MWD at Week 8 | 339.5 (227 to 392) | 360 (300 to 411) |
| Change in 6MWD from Baseline to Week 8 | 1.0 (-38.5 to 34.5) | 17.0 (-13 to 54) |
Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 4, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). This outcome measure was assessed using data from all subjects enrolled in the study, regardless of tablet strength availability at randomization. The six minute walk test was to be conducted 3 to 6 house after the previous dose of study drug. The Hodges-Lehmann median difference between treatment groups was used to estimate the treatment effect on 6MWD from Baseline to Week 4. A rank-based methodology was used instead of parametric-based methodology to avoid statistical bias caused by extreme outliers resulting from the handling of data that are missing due to death or clinical worsening of PAH. It is a more robust estimator than the between-treatment difference in medians.
| meters | Placebo | UT-15C (Oral Treprostinil) |
|---|---|---|
| 6MWD at Baseline | 338.5 (265.5 to 383.5) | 347 (288 to 387) |
| 6MWD at Week 4 | 339.5 (251 to 387) | 358 (288 to 403.2) |
| Change in 6MWD from Baseline to Week 4 | -4 (-31.5 to 20) | 7 (-13 to 42) |
Collected over Adverse events were recorded throughout the 12 week study which was conducted between October 2006 and April 2011.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 6/77 (7.8%) | 15/77 (19.5%) | 68/77 (88.3%) |
| UT-15C (Oral Treprostinil) | 9/151 (6%) | 27/151 (17.9%) | 138/151 (91.4%) |
| Event | Placebo | UT-15C (Oral Treprostinil) |
|---|---|---|
| right ventricular failureCardiac disorders | 3/77 | 10/151 |
| pulmonary hypertensionCardiac disorders | 4/77 | 3/151 |
| pneumoniaRespiratory, thoracic and mediastinal disorders | 3/77 | 1/151 |
| deathGeneral disorders | 2/77 | 2/151 |
| chest painMusculoskeletal and connective tissue disorders | 1/77 | 2/151 |
| pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/77 | 2/151 |
| hemoptysisRespiratory, thoracic and mediastinal disorders | 1/77 | 1/151 |
| cardio-respiratory arrestCardiac disorders | 1/77 | 0/151 |
| circulatory collapseCardiac disorders | 1/77 | 0/151 |
| collagen-vascular diseaseVascular disorders | 1/77 | 0/151 |
| Event | Placebo | UT-15C (Oral Treprostinil) |
|---|---|---|
| headacheNervous system disorders | 15/77 | 95/151 |
| diarrheaGastrointestinal disorders | 12/77 | 46/151 |
| nauseaGastrointestinal disorders | 14/77 | 45/151 |
| vomitingGastrointestinal disorders | 12/77 | 26/151 |
| flushingVascular disorders | 5/77 | 23/151 |
| dizzinessGeneral disorders | 11/77 | 17/151 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 6/77 | 21/151 |
| coughRespiratory, thoracic and mediastinal disorders | 9/77 | 14/151 |
| pain in jawMusculoskeletal and connective tissue disorders | 3/77 | 17/151 |
| pyrexiaInfections and infestations | 8/77 | 7/151 |
| Age, Categorical(Participants) | Placebo | UT-15C (Oral Treprostinil) | Total |
|---|---|---|---|
| <=18 years | 1 | 9 | 10 |
| Between 18 and 65 years | 69 | 141 | 210 |
| >=65 years | 7 | 1 | 8 |
| Age, Continuous(years) | Placebo | UT-15C (Oral Treprostinil) | Total |
|---|---|---|---|
| Mean | 42.5 ± 13.5 | 37.8 ± 13.5 | 39.4 ± 13.7 |
| Sex: Female, Male(Participants) | Placebo | UT-15C (Oral Treprostinil) | Total |
|---|---|---|---|
| Female | 58 | 108 | 166 |
| Male | 19 | 43 | 62 |
| PAH Etiology(participants) | Placebo | UT-15C (Oral Treprostinil) | Total |
|---|---|---|---|
| Idiopathic or heritable PAH | 56 | 114 | 170 |
| PAH associated w collagen vascular disease | 17 | 26 | 43 |
| PAH associated w repaired congenital heart defect | 3 | 10 | 13 |
| PAH associated w HIV infection | 1 | 1 | 2 |
| Baseline Six Minute Walk Distance(meters) | Placebo | UT-15C (Oral Treprostinil) | Total |
|---|---|---|---|
| Mean | 327.6 ± 70.7 | 331.3 ± 64.9 | 330.0 ± 66.8 |
| WHO Functional Classification(participants) | Placebo | UT-15C (Oral Treprostinil) | Total |
|---|---|---|---|
| WHO Class I | 1 | 1 | 2 |
| WHO Class II | 24 | 52 | 76 |
| WHO Class III | 52 | 98 | 150 |
The record gives a start of Oct 2006, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2013, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil
Pulmonary Arterial Hypertension →